Misoprostol in Pakistan Event at USAID

first_img ShareEmailPrint To learn more, read: Posted on January 10, 2011August 17, 2016Click to share on Facebook (Opens in new window)Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Reddit (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window)Trained traditional birth attendants in Pakistan provide misoprostol to prevent postpartum haemorrhage: a randomised placebo-controlled trialJill Durocher, Program Associate, Gynuity Health ProjectsJennifer Blum, Senior Program Associate, Gynuity Health ProjectsMonday, January 24, 20112:00-3:00 PMRonald Reagan Building1300 Pennsylvania Avenue, NWWashington, D.C. 20523Room: 4.8 E/FAbout the event: Postpartum haemorrhage (PPH) continues to be the leading single direct cause of maternal mortality worldwide. Despite global efforts to ensure that women deliver with skilled birth attendants and have access to conventional uterotonics for PPH prevention, 60% of births in low resource countries occur outside health facilities without a skilled attendant. In Pakistan, 65% of births occur at home and 27% of maternal deaths are attributed to PPH. Today’s talk summarizes results from a randomized controlled trial testing the impact of post-partum administration of 600 mcg oral misoprostol on PPH by Pakistani trained traditional birth attendants. The data show a 24% reduction in PPH among women given misoprostol after delivery. These results, in conjunction with other published reports on misoprostol for PPH prevention, support the drug’s effectiveness in preventing PPH in places where oxytocin is either not available or not feasible. We also hope that these results will bolster WHO support to list misoprostol for its specific PPH prevention indication on its Essential Medicines List.Jill Durocher will share results from this newly published trial and discuss its implication for programs introducing misoprostol for PPH prevention. Jennifer Blum will be on hand to discuss how this relates to Gynuity’s current portfolio of work on misoprostol for the prevention and treatment of PPH globally.Please join USAID and Gynuity Health Projects for this presentation—newly published in BJOG. All are invited. Please contact Tierra Smith (tsmith@usaid.gov) for pre-clearance into the building.Share this:last_img

Leave a Reply

Your email address will not be published. Required fields are marked *